Sanofi Reveals Late-Stage Data For Fitusiran In Hemophilia Patients
Agios Presents Mitapivat Long-Term Data On Hemoglobin Response, Transfusion Burden
Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients
Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients
ASH21 Recent News
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
Harpoon Shares Jump After Early Data From BCMA-Targeting Myeloma Candidate At ASH Meet
JNJ's Janssen Posts Two Years Survival Data On BCMA Cell Therapy In Multiple Myeloma
What Analysts Have To Say On Incremental IGM-2323 Data At ASH Presentation
IGM Biosciences' B Cell Malignancies Trial Data Fails To Lift The Stock
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
New Data At ASH21 Show Bluebird's Thalassemia Gene Therapy Potentially Curative One-Time Treatment
Bluebird Bio Posts Updated Data From Sickle Cell Gene Therapy Program
Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting